CST, 46336SF, Ly6k (E4K8Y) Rabbit Monoclonal Antibody (BSA and Azide Free)

Monoclonal Antibody for studying LY6K mouse. Validated for Western Blotting,IHC Leica Bond,Immunohistochemistry (Paraffin). Highly specific and rigorously validated in-house, Ly6k (E4K8Y) Rabbit Monoclonal Antibody (BSA and Azide Free) (CST #46336) is ready to ship. Product Usage Information This product is the carrier free version of product #44263. All data were generated using the same antibody clone in the standard formulation which contains BSA and glycerol. This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us . Optimal dilutions/concentrations should be determined by the end user. BSA and Azide Free antibodies are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity. Formulation Supplied in 1X PBS (10 mM Na 2 HPO 4 , 3 mM KCl, 2 mM KH 2 PO 4 , and 140 mM NaCl (pH 7.8)). BSA and Azide Free. For standard formulation of this product see product # 44263 Storage Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. Specificity / Sensitivity Ly6k (E4K8Y) Rabbit Monoclonal Antibody (BSA and Azide Free) recognizes endogenous levels of total Ly6k protein. Species Reactivity: Mouse Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro70 of murine Ly6k protein. Background Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3). Ly6k is a member of the Ly6/urokinase type plasminogen activator receptor-like protein (uPAR)(LU) superfamily. It is expressed in testes where in interaction with another (uPAR)(LU) family member, TEX101, it is proposed to be necessary for the production of viable sperm (4). The human ortholog of this protein, LY6K, has been characterized to be a CTA. It is found to be upregulated in numerous types of cancer, including esophageal squamous cell carcinoma, bladder cancer, and breast cancer (5,6). Alternate Names 2410015A16Rik; 3110035B01Rik; CT97; Ly-6K; Ly6k; lymphocyte antigen 6 complex, locus K; Lymphocyte antigen 6K; mLy-6; mLy-6K Specification REACTIVITY: M SENSITIVITY: Endogenous MW (kDa): 18 Source/Isotype: Rabbit IgG